Progression-free survival: An important prognostic marker for long-term survival of small cell lung cancer

Tuberculosis and Respiratory Diseases

Volumn 76, Issue 5, 2014, Pages 218-225

  Park, Myoung Rin ^a   Park, Yeon Hee ^b   Choi, Jae Woo ^b   Park, Dong Il ^b   Chung, Chae Uk ^b   Moon, Jae Young ^b   Park, Hee Sun ^b   Jung, Sung Soo ^b   Kim, Ju Ock ^b   Kim, Sun Young ^b   Lee, Jeong Eun ^b  

^a Department of Public Health Administration ^*  (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

Author keywords

Disease free survival; Prognosis; Small cell lung carcinoma

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; LACTATE DEHYDROGENASE;

ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM SURVIVAL; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SHORT TERM SURVIVAL; SMOKING; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84903165520     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2014.76.5.218     Document Type: Article

References (33)

1. Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev 2004;30:521-43. (Pubitemid 39157853)
2. Usuda K, Saito Y, Sagawa M, Sato M, Kanma K, Takahashi S, et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 1994;74:2239-44. (Pubitemid 24322277)
3. Tanaka K, Shimada H, Miura M, Fujii Y, Yamaguchi S, Endo I, et al Metastatic tumor doubling time: most important pre-hepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis. World J Surg 2004;28:263-70. (Pubitemid 38375526)
4. Kerr KM, Lamb D. Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. Br J Cancer 1984;50:343-9. (Pubitemid 14063885)
5. Ost D, Fein AM, Feinsilver SH. Clinical practice. The solitary pulmonary nodule. N Engl J Med 2003;348:2535-42. (Pubitemid 36712195)
6. Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 1990;61:584-9. (Pubitemid 20126340)
7. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-33. (Pubitemid 30640099)
8. Ando S, Suzuki M, Yamamoto N, Iida T, Kimura H. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res 2004;24:1941-6. (Pubitemid 38954614)
9. Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 2009;4:37-43.
10. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D, et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 2005;23:850-6. (Pubitemid 46224185)
11. Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - what limits limited disease? Lung Cancer 2002;37:271-6. (Pubitemid 35286725)
12. National Comprehensive Cancer Network. The NCCN clinical practice guidelines in oncology: small cell lung cancer (version V.II.2014) [Internet]. Fort Washington: National Comprehensive Cancer Network; 2013 [cited 2013 Oct 3]. Available from: http://www.nccn.org/professionals/physician-gls/pdf/sclc.pdf.
13. Wang CS, Sun CF. C-reactive protein and malignancy: clinicopathological association and therapeutic implication. Chang Gung Med J 2009;32:471-82.
14. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003;90:215-9. (Pubitemid 36237897)
15. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001;182:197-201. (Pubitemid 32907362)
16. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 2007;27:1091-7. (Pubitemid 47399443)
17. Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y, et al. Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 2007;27:3001-4. (Pubitemid 47228036)
18. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-7.
19. Milroy R, Shapiro D, Shenkin A, Banham SW. Acute phase reaction during chemotherapy in small cell lung cancer. Br J Cancer 1989;59:933-5. (Pubitemid 19155711)
20. Arpin D, Trillet-Lenoir V, Lasset C, Souquet PJ, Riou R, Yoanidis I, et al. [Value of C-reactive protein determination in small cell lung cancer]. Bull Cancer 1993;80:1063-8.
21. Hong S, Kang YA, Cho BC, Kim DJ. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J 2012;53:111-7.
22. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973;4:31-42.
23. Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067-77. (Pubitemid 350307898)
24. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics [Internet]. Rockville: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics evaluation and Research; 2007 [cited 2013 Oct 2]. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.
25. Bergmann L, Hirschfeld S, Morris C, Palmeri S, Stone A. Progression-free survival as an end-point in clinical trials of biotherapeutic agents. Eur J Cancer Suppl 2007;5:23-8. (Pubitemid 350186299)
26. Dancey JE, Dodd LE, Ford R, Kaplan R, Mooney M, Rubinstein L, et al. Recommendations for the assessment of progression in randomised cancer treatment trials. Eur J Cancer 2009;45:281-9.
27. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25:5218-24. (Pubitemid 350232253)
28. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10:162-70.
29. Amir E, Seruga B, Kwong R, Tannock IF, Ocana A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur J Cancer 2012;48:385-8.
30. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-96. (Pubitemid 41443406)
31. Johnson BE, Makuch RW, Simmons AD, Gazdar AF, Burch D, Cashell AW. myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines. Cancer Res 1988;48:5163-6.
32. Brennan J, O'Connor T, Makuch RW, Simmons AM, Russell E, Linnoila RI, et al. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 1991;51:1708-12.
33. Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 1997;65:284-97. (Pubitemid 27355857)